Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa for Presurgical Autologous Blood Donation
NCT00270023Phase 3Completed
- Sponsor
- Johnson & Johnson
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in anemia (4 arms), sponsored by Johnson & Johnson. Primary endpoints: Number of self-donated units of blood obtained within 11 days and Assessment of safety (laboratory tests, vital signs, and adverse events). Status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00270023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270023.